Circio Holding registers share capital increase from bond conversion

Circio Holding ASA announced on September 9, 2025, that the share capital increase resulting from the conversion of convertible bonds by Atlas Special Opportunities, LLC, as previously communicated on September 5, 2025, has been registered with the Norwegian Register of Business Enterprises. This registration formally updates the company's financial structure.

As a result of this conversion, Circio Holding's new share capital is NOK 65,305,046.40, divided into 108,841,744 shares, each with a nominal value of NOK 0.60.

Circio Holding is a biotechnology company focused on developing circular RNA vector expression technology for gene and cell therapies, alongside advancing its immuno-oncology program, TG01, which targets RAS-mutated cancers.